DaVita (NYSE:DVA) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next?

DaVita Inc. (NYSE:DVA) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $128.91 and traded as high as $150.22. DaVita shares last traded at $150.0610, with a volume of 640,484 shares.

Analysts Set New Price Targets

Several brokerages have recently commented on DVA. Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a research report on Monday, December 29th. UBS Group raised their price target on DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a report on Wednesday, February 4th. Zacks Research raised DaVita from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. Barclays raised their price target on DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 3rd. Finally, Truist Financial set a $158.00 price target on DaVita in a report on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, DaVita currently has a consensus rating of “Hold” and a consensus target price of $155.80.

DaVita Stock Performance

The firm has a 50 day simple moving average of $145.49 and a two-hundred day simple moving average of $128.91. The stock has a market cap of $10.02 billion, a P/E ratio of 15.14, a P/E/G ratio of 0.51 and a beta of 0.92.

DaVita (NYSE:DVA) last announced its earnings results on Monday, February 2nd. The company reported $3.40 earnings per share for the quarter, beating the consensus estimate of $3.24 by $0.16. The firm had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.51 billion. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.24 EPS. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. As a group, equities research analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

Institutional Trading of DaVita

Several hedge funds have recently added to or reduced their stakes in DVA. Elevation Wealth Partners LLC increased its position in shares of DaVita by 147.3% during the 4th quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after purchasing an additional 165 shares during the period. Caitlin John LLC acquired a new position in shares of DaVita during the 4th quarter valued at $34,000. Sankala Group LLC acquired a new position in shares of DaVita during the 4th quarter valued at $39,000. Canada Pension Plan Investment Board acquired a new position in shares of DaVita during the 2nd quarter valued at $43,000. Finally, Kestra Advisory Services LLC acquired a new position in shares of DaVita during the 4th quarter valued at $45,000. Institutional investors own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.